Increased basal ganglia binding of18F-AV-1451 in patients with progressive supranuclear palsy-Reference-Cited by-同舟云学术

Increased basal ganglia binding of18F-AV-1451 in patients with progressive supranuclear palsy

Published:2016-10-06 Issue:1 Volume:32 Page:108-114
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Smith Ruben¹,Schain Martin²,Nilsson Christer¹²,Strandberg Olof²,Olsson Tomas³,Hägerström Douglas⁴,Jögi Jonas⁵,Borroni Edilio⁶,Schöll Michael²⁷,Honer Michael⁶,Hansson Oskar²⁸

Affiliation:

1. Skåne University Hospital, Department of Neurology; Lund Sweden

2. Lund University, Clinical Memory Research Unit, Department of Clinical Sciences Malmö; Malmö Sweden

3. Skåne University Hospital, Department of Radiation Physics; Lund Sweden

4. Skåne University Hospital, Department of Clinical Neurophysiology; Lund Sweden

5. Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine; Lund Sweden

6. Roche Pharmaceutical Research and Early Development, Neuroscience Discovery & Biomarkers, Roche Innovation Center; Basel Switzerland

7. MedTech West and the University of Gothenburg, Department of Clinical Neuroscience; Gothenburg Sweden

8. Skåne University Hospital, Memory Clinic; Malmö Sweden

Funder

H2020 European Research Council

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26813/fullpdf

Reference24 articles.

1. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia;Steele;Arch Neurol,1964

2. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges;Williams;Lancet Neurol,2009

3. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy;Arai;Acta Neuropathol,2001

4. Variation in tau isoform expression in different brain regions and disease states;Majounie;Neurobiol Aging,2013

5. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases;Respondek;Mov Disord,2014

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies;Alzheimer's & Dementia;2024-09-12

2. Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy;Neurochemical Research;2024-06-06

3. A novel MAPT variant (E342K) as a cause of familial progressive supranuclear palsy;Frontiers in Neurology;2024-04-19

4. Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy;NeuroImage;2024-02

5. A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles;Brain Communications;2023-11-16